Inspire Medical Systems Reports Q2 2026 Revenue Decline, Achieves Net Income Turnaround

Inspire Medical Systems, Inc. reported its financial results for the second quarter of 2026, revealing a revenue of $200.6 million, a decrease of 7.6% compared to $217.1 million in the same period last year. For the first half of 2026, total revenue was $405.2 million, down 3.2% from $418.4 million in the first half of 2025. The decline in revenue was primarily attributed to challenges related to coding and reimbursement, particularly affecting U.S. sales, which fell by 9.6% year-over-year. Despite the revenue drop, the company achieved a gross profit margin of 85.5% for the quarter, an increase from 84.0% in the prior year, largely due to a higher sales mix of the Inspire V system, which has a superior gross margin compared to its predecessor.

In terms of profitability, Inspire Medical Systems reported a net income of $314,000 for the second quarter, a significant turnaround from a net loss of $3.6 million in the same quarter of 2025. However, for the first half of 2026, the company recorded a net loss of $11 million, compared to a loss of $600,000 in the first half of 2025. The effective tax rate for the second quarter was notably high at 89.9%, driven by shortfalls related to stock-based compensation. The company’s operating loss for the quarter was $514,000, a marked improvement from a loss of $3.3 million in the prior year.

Operationally, Inspire Medical Systems has been focusing on expanding its sales and marketing efforts. As of June 30, 2026, the company had 280 U.S. sales territories and 301 field clinical representatives, an increase from 295 territories and 275 representatives at the end of 2025. This expansion is part of a broader strategy to enhance therapy awareness and drive adoption of the Inspire therapy. The company also announced a strategic growth plan, Project Horizon, aimed at streamlining operations and optimizing the supply chain, with expected pre-tax restructuring charges of $20 million to $25 million.

Inspire Medical Systems continues to face challenges in the reimbursement landscape, particularly with the implementation of new coding requirements and the Wasteful and Inappropriate Service Reduction Model (WISeR) program, which has led to delays in revenue. The company is actively engaging with stakeholders to address these issues and is working towards establishing a separate CPT code for its Inspire V therapy. Looking ahead, Inspire anticipates that these reimbursement uncertainties will continue to impact revenue for the remainder of 2026, although it remains optimistic about the long-term growth potential of its Inspire system, especially with the increasing prevalence of GLP-1 medications for obesity, which may lead to more patients seeking treatment for obstructive sleep apnea.